menu
    • menu
    [{"orgOrder":0,"company":"Guangzhou Fermion Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"FZ007-119","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Guangzhou Fermion Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Guangzhou Fermion Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Guangzhou Fermion Technology \/ Not Applicable"},{"orgOrder":0,"company":"Guangzhou Fermion Technology","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"FZ002-037","moa":"SSTR4","graph1":"Neurology","graph2":"Phase I","graph3":"Guangzhou Fermion Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Guangzhou Fermion Technology \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Guangzhou Fermion Technology \/ Jiangsu Simcere Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Guangzhou Fermion Technology

    Menu

    Guangzhou Fermion Technology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Guangzhou Fermion Technology

                            China arrow
                            BioAsia
                            Not Confirmed

                            Guangzhou Fermion Technology

                            China arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FZ002-037

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Jiangsu Simcere Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Fermion, Simcere Exclusive License for China’s First SSTR4 Agonist

                            Details : Under the agreement, Simcere will gain exclusive rights to develop and commercialize FZ002-037 in Greater China. It is being evaluated for the treatment of Chronic Pain.

                            Product Name : FZ002-037

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 17, 2025

                            Lead Product(s) : FZ002-037

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Jiangsu Simcere Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Guangzhou Fermion Technology

                            China arrow
                            BioAsia
                            Not Confirmed

                            Guangzhou Fermion Technology

                            China arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FZ007-119

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fermion's TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA

                            Details : FZ007-119 is a third-generation JAK inhibitor targeting TYK2 JH2. It's IND application is approved after preclinical studies for plaque psoriasis, inflammatory bowel disease & rheumatoid arthritis

                            Product Name : FZ007-119

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 05, 2024

                            Lead Product(s) : FZ007-119

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth